Phase 4 Vasculitis Trial, Recruiting NCT06611696 Sponsor: Chiba University Condition: Vasculitis
Back to Vasculitis

Phase 4 Vasculitis Trial, Recruiting

NCT06611696
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been recently diagnosed with a condition called ANCA-associated vasculitis (specifically granulomatosis with polyangiitis or microscopic polyangiitis), based on recognised medical definitions
  • You have had a positive blood test showing the presence of specific antibodies linked to this condition (called PR3-ANCA or MPO-ANCA)
  • You or a family member/representative is able to sign a consent form agreeing to take part

Who may not be able to join:

  • You have already received treatment for ANCA-associated vasculitis before entering the trial
  • Your kidneys are very severely affected by this condition, or you are experiencing serious lung bleeding requiring high levels of oxygen
  • You have another condition where your immune system attacks your own body (another autoimmune disease affecting multiple parts of the body)
  • You are known to have HIV, or have a history of hepatitis B or hepatitis C infection
  • You are pregnant, breastfeeding, or wish to become pregnant
  • You have had cancer in the past 5 years, or have any signs of cancer currently
  • You have had active tuberculosis (TB) in the past year, or currently show signs of it
  • You have had a severe allergic reaction to a type of medication called a monoclonal antibody
  • You have another health condition that is likely to need treatment with steroids, immune-suppressing drugs, certain specialist therapies, or similar medications
  • You have used a B cell-depleting medication (such as rituximab or belimumab) in the past 6 months
  • You have previously taken a medication called avacopan
  • You are unable to swallow the trial medications (avacopan and prednisolone) as tablets
  • The trial doctor feels there is another reason that makes it inappropriate for you to join (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Masayoshi Harigai, MD, PhD, International University of Health and Welfare

Phone: 81+43-222-7171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Chiba University
Registry
ClinicalTrials.gov
Start date
15 November 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Proportions of patients achieving remission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov